{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:27:33Z","timestamp":1793334453970,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["KYQN2024007"],"award-info":[{"award-number":["KYQN2024007"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cellsig.2025.112263","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:12:26Z","timestamp":1764202346000},"page":"112263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11\/CCR3 axis in lenvatinib-treated hepatocellular carcinoma"],"prefix":"10.1016","volume":"138","author":[{"given":"Na","family":"Qiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kanogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahisa","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cellsig.2025.112263_bb0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112263_bb0010","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3748\/wjg.v20.i10.2515","article-title":"Hepatic inflammation and progressive liver fibrosis in chronic liver disease","volume":"20","author":"Czaja","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"48","key":"10.1016\/j.cellsig.2025.112263_bb0015","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.3748\/wjg.v22.i48.10512","article-title":"Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets","volume":"22","author":"Zhang","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112263_bb0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/liv.12465","article-title":"Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever","volume":"34","author":"Carloni","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.cellsig.2025.112263_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107823","article-title":"Targeting endoplasmic reticulum proteostasis in liver fibrosis: from signaling mechanisms to therapeutic opportunities","volume":"217","author":"Kong","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.hbpd.2024.09.003","article-title":"Fibrotic liver extracellular matrix induces cancerous phenotype in biomimetic micro-tissues of hepatocellular carcinoma model","volume":"24","author":"Nouri","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112263_bb0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1349-7006.2009.01087.x","article-title":"Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma","volume":"100","author":"Amann","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellsig.2025.112263_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12876-015-0291-5","article-title":"Hepatic stellate cells: central modulators of hepatic carcinogenesis","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"10.1016\/j.cellsig.2025.112263_bb0045","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1053\/j.gastro.2020.12.015","article-title":"Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production","volume":"160","author":"Myojin","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellsig.2025.112263_bb0050","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.canlet.2020.02.012","article-title":"Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-ROR\u03b1-Wnt\/\u03b2-catenin axis","volume":"476","author":"Huang","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112263_bb0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/labinvest.2013.139","article-title":"Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model","volume":"94","author":"Zhao","year":"2014","journal-title":"Lab. Investig."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112263_bb0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/HEP.0000000000001021","article-title":"CX3CR1 + macrophages interact with HSCs to promote HCC through CD8 + T-cell suppression","volume":"82","author":"Jeong","year":"2025","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112263_bb0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.hbpd.2024.09.006","article-title":"Nomogram for prediction of hepatocellular carcinoma recurrence after liver resection","volume":"24","author":"Zhang","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.cellsig.2025.112263_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.hbpd.2025.07.002","article-title":"circ0006646 serves as a robust prognostic biomarker for post-transplant tumor recurrence and survival in hepatocellular carcinoma patients","author":"Chen","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.cellsig.2025.112263_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000546138","article-title":"Current perspectives on perioperative combination therapy for hepatocellular carcinoma","author":"Nishio","year":"2025","journal-title":"Liver Cancer"},{"issue":"15","key":"10.1016\/j.cellsig.2025.112263_bb0080","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10126","key":"10.1016\/j.cellsig.2025.112263_bb0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with Transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"67","key":"10.1016\/j.cellsig.2025.112263_bb0095","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","author":"Wu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cellsig.2025.112263_bb0100","series-title":"Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study. Liver Cancer","first-page":"1","author":"Pan","year":"2025"},{"key":"10.1016\/j.cellsig.2025.112263_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217472","article-title":"Drug resistance in TKI therapy for hepatocellular carcinoma: mechanisms and strategies","volume":"613","author":"Jiang","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112263_bb0110","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cellsig.2025.112263_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104069","article-title":"New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma","volume":"29","author":"Fan","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0120","doi-asserted-by":"crossref","first-page":"26432","DOI":"10.1038\/s41598-024-74650-8","article-title":"Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0125","doi-asserted-by":"crossref","first-page":"2503645","DOI":"10.1080\/07853890.2025.2503645","article-title":"Discovery of novel diagnostic biomarkers of hepatocellular carcinoma associated with immune infiltration","volume":"57","author":"Liu","year":"2025","journal-title":"Ann. Med."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112263_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70789","article-title":"Chemokines: orchestration of the tumor microenvironment and control of hepatocellular carcinoma progression","volume":"14","author":"Yang","year":"2025","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112263_bb0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2015.06.017","article-title":"Role of chemokine pathways in hepatobiliary cancer","volume":"379","author":"Ehling","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/HEP.0000000000000287","article-title":"Regulatory role and translational potential of CCL11 in liver fibrosis","volume":"78","author":"Kong","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cellsig.2025.112263_bb0145","article-title":"C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease","volume":"5","author":"Fan","year":"2023","journal-title":"JHEP Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1535-7163.MCT-17-0507","article-title":"CCL26 participates in the PRL-3-induced promotion of colorectal cancer invasion by stimulating tumor-associated macrophage infiltration","volume":"17","author":"Lan","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112263_bb0155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.28655","article-title":"Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26","volume":"64","author":"Chiu","year":"2016","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.cellsig.2025.112263_bb0160","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112263_bb0165","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.cellsig.2025.112263_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.cellsig.2025.112263_bb0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","article-title":"The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112263_bb0180","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112263_bb0185","first-page":"C1150","article-title":"Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis","volume":"327","author":"Ao","year":"2024","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.cellsig.2025.112263_bb0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbrc.2021.02.097","article-title":"Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells","volume":"549","author":"Ao","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112263_bb0195","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/liv.15953","article-title":"Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy","volume":"44","author":"Qin","year":"2024","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112263_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104069","article-title":"New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma","volume":"29","author":"Fan","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.cellsig.2025.112263_bb0205","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112263_bb0210","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.32899","article-title":"Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma","volume":"147","author":"Ruan","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.cellsig.2025.112263_bb0215","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.jid.2020.02.023","article-title":"Pivotal involvement of the CX3CL1-CX3CR1 axis for the recruitment of M2 tumor-associated macrophages in skin carcinogenesis","volume":"140","author":"Ishida","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cellsig.2025.112263_bb0220","doi-asserted-by":"crossref","first-page":"1237715","DOI":"10.3389\/fimmu.2023.1237715","article-title":"The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy","volume":"14","author":"Chaudhri","year":"2023","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.cellsig.2025.112263_bb0225","doi-asserted-by":"crossref","first-page":"27394","DOI":"10.18632\/oncotarget.8423","article-title":"Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112263_bb0230","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-16-0520","article-title":"Loss of SMAD4 promotes lung metastasis of colorectal Cancer by accumulation of CCR1+ tumor-associated neutrophils through CCL15-CCR1 Axis","volume":"23","author":"Yamamoto","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.cellsig.2025.112263_bb0235","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s10238-022-00888-z","article-title":"Role of chemokines in the crosstalk between tumor and tumor-associated macrophages","volume":"23","author":"Qin","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0240","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.30134","article-title":"CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.cellsig.2025.112263_bb0245","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1158\/1078-0432.CCR-18-3421","article-title":"Breast Phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy","volume":"25","author":"Nie","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112263_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000209","article-title":"Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma","volume":"7","author":"Yamada","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0255","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112263_bb0260","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13046-021-02133-z","article-title":"Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy","volume":"40","author":"Jensen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.cellsig.2025.112263_bb0265","article-title":"The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability","volume":"4","author":"Roy","year":"2023","journal-title":"Cell Rep. Med."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825006783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825006783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:53:46Z","timestamp":1766138026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656825006783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":53,"alternative-id":["S0898656825006783"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112263","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11\/CCR3 axis in lenvatinib-treated hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112263"}}